CRVO icon

CervoMed

8.73 USD
+0.23
2.71%
Updated Jul 31, 12:58 PM EDT
1 day
2.71%
5 days
8.99%
1 month
38.79%
3 months
-3.64%
6 months
286.28%
Year to date
291.48%
1 year
-32.85%
5 years
-89.88%
10 years
-99.82%
 

About: CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Employees: 15

0
Funds holding %
of 7,324 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

504% more capital invested

Capital invested by funds: $3.46M [Q4 2024] → $20.9M (+$17.4M) [Q1 2025]

8.24% more ownership

Funds ownership: 18.01% [Q4 2024] → 26.24% (+8.24%) [Q1 2025]

8% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 13

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

2% less funds holding

Funds holding: 46 [Q4 2024] → 45 (-1) [Q1 2025]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$10
15%
upside
Avg. target
$17.33
99%
upside
High target
$27
209%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Canaccord Genuity
Sumant Kulkarni
209%upside
$27
Buy
Maintained
29 Jul 2025
D. Boral Capital
Jason Kolbert
15%upside
$10
Buy
Maintained
28 Jul 2025
Chardan Capital
Daniil Gataulin
72%upside
$15
Buy
Maintained
12 May 2025

Financial journalist opinion

Based on 4 articles about CRVO published over the past 30 days

Positive
Benzinga
3 days ago
CervoMed's Dementia Data Show Slowed Disease Progression
CervoMed Inc. CRVO on Monday shared 32-week data from the Extension phase of its Phase 2b RewinD-LB trial evaluating oral neflamapimod in patients with Dementia with Lewy Bodies (DLB).
CervoMed's Dementia Data Show Slowed Disease Progression
Positive
Zacks Investment Research
3 days ago
CERVOMED INC (CRVO) Surges 11.6%: Is This an Indication of Further Gains?
CERVOMED INC (CRVO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CERVOMED INC (CRVO) Surges 11.6%: Is This an Indication of Further Gains?
Neutral
GlobeNewsWire
3 days ago
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at Week 32 of treatment (p=0.0037). This risk reduction improved to 64% (p=0.0001) among patients who have minimal evidence of AD co-pathology (ptau181 < 2.2 pg/mL at screening)
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
Neutral
GlobeNewsWire
3 weeks ago
CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025
BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver Developing Topics (late-breaking) virtual and in-person poster presentations at Alzheimer's Association® International Congress (AAIC) 2025, being held on July 27 – 31, 2025 in Toronto, Canada. The Company will be presenting the results, including new results, from the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB).
CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025
Negative
Zacks Investment Research
2 months ago
CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates
CervoMed Inc. (CRVO) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.41 per share a year ago.
CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
2 months ago
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB)
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Positive
Seeking Alpha
4 months ago
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 300% in Q1 2025 due to positive Phase 2b trial results for its lead drug candidate, neflamapimod despite earlier setbacks. Chimerix Inc. gained over 144% after announcing an acquisition by Jazz Pharmaceuticals and positive FDA feedback on its lead drug candidate, dordaviprone.
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
Neutral
GlobeNewsWire
4 months ago
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™), being held on April 1-5, 2025 in in Vienna, Austria. The Company will be presenting detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB).
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)
Positive
Seeking Alpha
4 months ago
CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats
CervoMed's stock surged more than 400% after interim data showed significant improvement with a new batch of neflamapimod in treating Dementia with Lewy Bodies. The recent interim readout deserves excitement, but I do express several concerns related to, among others, potential learning and placebo effects, subjective CDR-SB results, and lack of biomarker data. CervoMed is well-funded into 2026, but may need additional funds for further trials to bring neflamapimod to market for DLB.
CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats
Neutral
GlobeNewsWire
4 months ago
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
Charts implemented using Lightweight Charts™